ESLA Q3 2025 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$5M

Net Income

-$5M

EPS (Diluted)

$-0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$727,332

Free Cash Flow

-$727,332

Stock-Based Comp.

$152,421

Balance Sheet

Total Assets

$4M

Total Liabilities

$13M

Stockholders' Equity

-$10M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$5M	-$3M	-42.2%
Net Income	-$5M	-$3M	-42.2%